Meeting
2016 ASCO Annual Meeting
Bevacizumab plus chemotherapy (bev/CT) as first-line therapy for patients with potentially resectable metastatic colorectal cancer (mCRC): Final results of the French noninterventional PICASSO study.
Authors
David Malka
Gustave Roussy Cancer Campus, Villejuif, France
David Malka , Jean-Philippe Metges , Dominique Elias , Jaafar Bennouna , Franck Bonnetain , Louis-Marie Dourthe , Meher Ben Abdelghani , Abderraouf Radji , Philippe Laplaige , Fabien Petit Laurent , Vanessa Barue , Sophie Gandon , Michel Rivoire
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01343901
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3554)
DOI
10.1200/JCO.2016.34.15_suppl.3554
Abstract #
3554
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2019 ASCO Annual Meeting
Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.
First Author: Lisa Salvatore
Poster
2015 Gastrointestinal Cancers Symposium
Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
First Author: Satoshi Yuki